NASDAQ: ELTXElicio Therapeutics Inc Stock
$1.92+0.10 (+5.49%)
Updated Oct 1, 2026
ELTX Price
$1.92
Fair Value Price
$0.26
Market Cap
$50.46M
52 Week Low
$1.71
52 Week High
$16.00
P/E
-0.88x
P/B
6.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.95
Operating Cash Flow
-$38M
Beta
0.93
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ELTX Overview
Angion is a clinical-stage biopharmaceutical company developing small molecule therapeutics to address fibrotic diseases and acute organ injuries. Its lead program is ANG-3070. Angion was founded in 1998 and headquartered in Uniondale, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELTX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELTX
Ranked#337 of 464
Ranked#337 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.84 | A | |
| $8.21 | A | |
| $39.57 | A |
Be the first to know about important ELTX news, forecast changes, insider trades & much more!
ELTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELTX ($1.92) is overvalued by 625.76% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELTX ($1.92) is not significantly undervalued (625.76%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELTX due diligence checks available for Premium users.
Valuation
ELTX fair value
Fair Value of ELTX stock based on Discounted Cash Flow (DCF)
Price
$1.92
Fair Value
$0.26
Overvalued by
625.76%
ELTX ($1.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELTX ($1.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.88x
Industry
8.71x
Market
48.27x
ELTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.36x
Industry
5.13x
ELTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
ELTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$31.3M
Liabilities
$23.4M
Debt to equity
2.95
ELTX's short-term assets ($25.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELTX's short-term assets ($25.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ELTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
$0.0
Financing
$16.5M
ELTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELTX vs Biotech Stocks
Elicio Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.